{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Status:
Investigational
Source:
NCT01705847: Phase 1 Interventional Completed Lymphoid Malignancies
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
GS-9820 (formerly CAL-120) is an oral, small molecule delta selective Phosphatidylinositol 3-kinases (PI3 kinase) inhibitor, a first in class compound, with greater than 200-fold selectivity in cell-based assays for the delta isoform as compared to other class isoforms. GS-9820 is designed to induce cancer cell death and inhibit signaling pathways associated with cancer cell dependence on the tumor microenvironment. GS-9820 is on the phase I of clinical trial, where has to be determined the appropriate dosing regimen of drug in subjects with lymphoid malignancies.
Status:
Investigational
Source:
NCT00862888: Phase 2 Interventional Completed Erectile Dysfunction
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
PF-00446687 is the highly selective, brain-penetrant, melanocortin 4 receptor (MC4R) agonist. PF-00446687 induced partner preferences formation in females prairie voles after a 6-h cohabitation without mating. PF-00446687 had been in phase I clinical trial for the treatment of sexual function disorders.
Status:
Investigational
Source:
NCT01954615: Phase 1 Interventional Completed Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
ACT-281959 (molecular weight 850.9 g/mol), the di-ester prodrug of
ACT-246475 (molecular weight 618.6 g/mol), was developed to improve absorption after oral dosing and is rapidly converted by esterases in vivo to ACT-246475 in two-steps via the formation of ACT-409100 (molecular weight 734.7 g/mol), the mono-ester prodrug. ACT-281959 is a novel potent and selective P2Y12 receptor antagonist with a wider therapeutic window. ACT-281959 showed antithrombotic efficacy after oral administration in the rat ferric chloride model. ACT-281959 entered clinical studies in healthy volunteers. ACT-281959 had been in phase I clinical trials by Actelion for the treatment of thrombosis. But there is no development reported for this study recently.
Status:
Investigational
Source:
NCT04701216: Phase 1 Interventional Completed Healthy Volunteers
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02019485: Phase 1 Interventional Completed Healthy
(2010)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
NCT00963053: Phase 2 Interventional Completed Primary Dysmenorrhea
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01029795: Phase 2 Interventional Terminated Diabetes Mellitus, Type 2
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01652742: Phase 1 Interventional Completed Healthy
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01449591: Phase 2 Interventional Completed Erythemato-telangiectatic Rosacea
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01582815: Phase 2 Interventional Completed Major Depressive Disorder
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
ADX-71149 (JNJ-40411813), a phenylpiperidine-substituted pyridone, is positive allosteric modulator (PAM) metabotropic glutamate type 2 (mGlu2) receptor activity. In fed rats, JNJ-40411813 was rapidly absorbed with an absolute oral bioavailability of 31%. ADX-71149 (JNJ-40411813) demonstrates antipsychotic activity in vivo rodents experiments. ADX-71149 (JNJ-40411813) is being jointly developed by Addex Therapeutics and Janssen Pharmaceuticals, a Johnson & Johnson company, for the treatment of epilepsy. Addex Therapeutics was also developing the candidate for schizophrenia, major depressive disorder and anxiety disorders. However, development in these indications has been discontinued.
